Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study

Avantor bags awards at Asia-Pacific Biopharma Excellence Awards 2025

Awards highlight Avantor's commitment to the Biopharma industry

Asahi Kasei Life Science begins operation

Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture

NCLT approves amalgamation of Cohance Lifesciences into and with Suven Pharmaceuticals

The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates

Lonza implements streamlined operating model

Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy

Merck seeks FDA approval for subcutaneous pembrolizumab

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851

Merck inks $200 million deal for Hengrui's midstage heart disease drug

Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region

SMS Pharmaceuticals completes USFDA inspection at Hyderabad facility

The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483

Entero launches ‘HealthEdge’ programme to empower Retail Chemists